Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Christian Lorson
Indiana Univ Purdue Univ at Indianapolis, Department: Dermatology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Shift Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
As described in Dr. Lorson’s disclosure, he is Co-founder and Chief Scientific Officer of Shift Pharmaceuticals. Shift Pharmaceuticals is a start-up biotechnology company based upon the intellectual property that Dr. Lorson generated at MU. His research at MU involves the development of novel therapeutics for a rare pediatric genetic disease called Spinal Muscular Atrophy (SMA). Shift Pharmaceuticals will be submitting NIH and foundation-based grants to fund the further development of the lead candidate for SMA. The project will involve the Lorson lab being responsible for in vivo testing of novel compounds designed to increase SMN levels as a treatment for Spinal Muscular Atrophy. It is the determination of the University of Missouri’s Conflict of Interest Committee that Dr. Lorson’s equity interest with the entity could directly affect the design, conduct and reporting of the research.
Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA
Spinal muscular atrophy (SMA) is an inherited neuromuscular disease that causes progressive muscle weakness that can eventuate in death of babies and older children. We discovered and characterized a series related chemicals that increase levels of the protein called SMN, which is deficient in SMA. The purpose of this grant is to analyze the drug-like properties of this series of active compounds, select the best for administration in mouse models of SMA, and to perform the key proof of principle experiments which, if successful, will lead to human trials of a novel agent for treatment of SMA.
Filed on February 08, 2018.
Tell us what you know about Christian Lorson's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Christian Lorson filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Christian Lorson | University of Missouri Columbia | Conflict of Interest | Shift Pharmaceuticals | Value cannot be readily determined |
| Christian Lorson | Brigham and Women's Hospital | Conflict of Interest | Shift Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.